Bringing new medicines to market despite subjective endpoints
b'In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals. Seth and Mike explored the two programs Tonix are currently developing in pain and psychiatry, areas where many larger companies have turned their back due to subjective endpoints. Tonix believes they have developed invaluable expertise to counter these challenges and Seth explains that the difficulty of the endpoints, will be compensated by the importance of bringing new medicines to market that will be significant to the pharmacopeia. Tonix is also working on a vaccine candidate for COVID-19 that is one of only a handful which is a live replicating virus vector platform. Seth discussed what the vaccine landscape might look like once COVID vaccines come to market and the adoption challenges we may face as a society. Seth also touched on the trend currently in the industry of biotechnology companies choosing to commercialise their products, how Tonix intend to do just this and discusses how technology has eroded big pharma\\u2019s advantage in this area.
Hosted on Acast. See acast.com/privacy for more information.
'